Citi Maintains Buy on Bristol-Myers Squibb

Citi is out with its report today on Bristol-Myers Squibb BMY, maintaining Buy. In a note to clients, Citi writes, "We rate BMY stock Buy/Medium Risk (1M). BMY offers a strong stable of late-stage pipeline assets (Yervoy, Eliquis, Nnulogix, dapagliflozin, Orencia subcutaneous), which we believe has the Company well-positioned to grow earnings off of its 2013 trough year. The company is also supported by an attractive ~5% dividend yield and has a management team that is focused on increasing shareholder value." Shares of BMY closed Friday at $29.12, down 0.85% from Thursday's close.